Ruti Sella1,2, Merih Oray3, Ronit Friling4,5, Lewaa Umar4, Ilknur Tugal-Tutkun3, Michal Kramer4,5. 1. Department of Ophthalmology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, 49100, Israel. rutibd@gmail.com. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. rutibd@gmail.com. 3. Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 4. Department of Ophthalmology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, 49100, Israel. 5. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
PURPOSE: The purpose of this study was to investigate the safety and effectiveness of an intravitreally injected dexamethasone-containing implant (Ozurdex(®)) in the treatment of uveitis in children. METHODS: The study group included ten patients (14 eyes) aged 6.5-15 years (mean age 12 years) with intermediate or posterior uveitis who were treated with the Ozurdex implant at two tertiary medical centers between 2009 and 2014, following an insufficient response to standard uveitis therapy. All were followed for at least 6 months (mean 12.2 ± 4.9 months). Clinical data before and after treatment were collected retrospectively from the medical files. Outcome measures were best corrected visual acuity, vitreous haze, and macular thickness. Ocular complications were documented. RESULTS: Visual acuity improved in 12 eyes (86 %) and intraocular inflammation decreased in 13 eyes (93 %) from 1 week to 3 months after the first injection. Macular edema decreased in all eyes from 1 month to 3 months after the first injection. Five patients underwent repeated injections because of an increase in macular thickness at 3-6 month follow-up. Complications included cataract progression in one patient after one injection and cataract formation in two patients after two injections, and an elevation in intraocular pressure in two patients who responded well to topical treatment. CONCLUSIONS: Both single and repeated injections of a dexamethasone-containing implant are safe and effective for the treatment of noninfectious intermediate and posterior uveitis in children. The duration of the beneficial effect may be limited. More data are required to establish the safety profile of the implant in the pediatric age group.
PURPOSE: The purpose of this study was to investigate the safety and effectiveness of an intravitreally injected dexamethasone-containing implant (Ozurdex(®)) in the treatment of uveitis in children. METHODS: The study group included ten patients (14 eyes) aged 6.5-15 years (mean age 12 years) with intermediate or posterior uveitis who were treated with the Ozurdex implant at two tertiary medical centers between 2009 and 2014, following an insufficient response to standard uveitis therapy. All were followed for at least 6 months (mean 12.2 ± 4.9 months). Clinical data before and after treatment were collected retrospectively from the medical files. Outcome measures were best corrected visual acuity, vitreous haze, and macular thickness. Ocular complications were documented. RESULTS: Visual acuity improved in 12 eyes (86 %) and intraocular inflammation decreased in 13 eyes (93 %) from 1 week to 3 months after the first injection. Macular edema decreased in all eyes from 1 month to 3 months after the first injection. Five patients underwent repeated injections because of an increase in macular thickness at 3-6 month follow-up. Complications included cataract progression in one patient after one injection and cataract formation in two patients after two injections, and an elevation in intraocular pressure in two patients who responded well to topical treatment. CONCLUSIONS: Both single and repeated injections of a dexamethasone-containing implant are safe and effective for the treatment of noninfectious intermediate and posterior uveitis in children. The duration of the beneficial effect may be limited. More data are required to establish the safety profile of the implant in the pediatric age group.
Authors: D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum Journal: Am J Ophthalmol Date: 2000-10 Impact factor: 5.258
Authors: Elizabeth A Sugar; Douglas A Jabs; Michael M Altaweel; Sue Lightman; Nisha Acharya; Albert T Vitale; Jennifer E Thorne Journal: Am J Ophthalmol Date: 2011-09-08 Impact factor: 5.258
Authors: Marc D de Smet; Simon R J Taylor; Bahram Bodaghi; Elisabetta Miserocchi; Philip I Murray; Uwe Pleyer; Manfred Zierhut; Talin Barisani-Asenbauer; Phuc LeHoang; Sue Lightman Journal: Prog Retin Eye Res Date: 2011-07-22 Impact factor: 21.198
Authors: Janine A Smith; Friederike Mackensen; H Nida Sen; Julie F Leigh; Angela S Watkins; Dmitry Pyatetsky; Howard H Tessler; Robert B Nussenblatt; James T Rosenbaum; George F Reed; Susan Vitale; Justine R Smith; Debra A Goldstein Journal: Ophthalmology Date: 2009-08 Impact factor: 12.079
Authors: Ahmed Sallam; Richard M Comer; John H Chang; John R Grigg; Richard Andrews; Peter J McCluskey; Susan Lightman Journal: Arch Ophthalmol Date: 2008-02
Authors: Maziar Mohammadi; Kisha Patel; Seyedeh P Alaie; Ron B Shmueli; Cagri G Besirli; Ronald G Larson; Jordan J Green Journal: Acta Biomater Date: 2018-04-21 Impact factor: 8.947